ESMO Media Releases

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer

Treatment with the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival

Biological medicines are responsible for some of the most promising innovations in cancer treatment

Immunotherapy has been a major breakthrough in oncology, with registered drugs now approved for use in an increasing number of tumour types

Chemotherapy is known to have a negative impact on the reproductive potential of young breast cancer patients. Its effects on women’s post-treatment fertility, however, are still poorly understood.

Most people with lung cancer are unaware of the benefits of regular exercise, yet new data show it can significantly reduce fatigue and improve well being.

Including exercise or sport as part of cancer care can significantly improve symptom management, quality of life and fitness during and after treatment, French researchers have concluded in two presentations to be reported at the ESMO 2018 Congress in Munich.

Results from the EDIFICE 6 survey identified major social and behavioural indicators for reluctance to undergo cancer screening tests in the French population

Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity

Securing access to optimal cancer care for all patients can only be achieved through integrated, sustainable translation of today’s scientific advances into tomorrow’s treatments

Some European countries take more than twice as long as others to reach HTA decisions to reimburse new cancer drugs following their approval by the EMA